Thoracic Paravertebral Block for Postoperative Analgesia After Video-assisted Thoracic Surgery.

Thoracic Paravertebral Block: a Comparative Study of Ropivacaine With Ropivacaine and Sufentanil for Treating Pain After Video-assisted Thoracic Surgery.

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01082744

Acronym

PARAVI

Enrollment

Registered

2010-03-09

Start date

2010-03-31

Completion date

2014-12-31

Last updated

2025-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain, Postoperative

Keywords

Paravertebral Block, Regional Anesthesia, Anesthetics Local, Ropivacaine, Sufentanil, Pain Postoperative, Chronic Pain, Thoracic Surgery Video-Assisted.

Brief summary

The use of paravertebral catheters is a recommended technique to achieve postoperative analgesia after thoracic surgery. To date there is no consensus on which drug regime (local anesthetics with or without opioid) is best. The aim of this prospective clinical trial is to determine wether the use of ropivacaine and sufentanil injected through a thoracic paravertebral catheter results in decreased acute postoperative pain compared with plain ropivacaine in patients after thoracoscopic lung surgery.

Interventions

DRUGRopivacaine + Sufentanil

Sufentanil at 0.25 µg/ml added to ropivacaine at 2 mg/ml at a perfusion rate of 0.15 ml/kg/h for continuous paravertebral block over 48 hours

DRUGRopivacaine

Ropivacaine at 2 mg/ml at a perfusion rate of 0.15 ml/kg/h for continuous paravertebral block over 48 hours

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patient scheduled for planned video-assisted thoracic surgery * Patient that consent to participate * Planned placement of paravertebral catheter * Patient having a medical insurance

Exclusion criteria

* Patient less than 18 years * Refusal to participate * Known pregnancy * Known allergies to local anesthetics, sufentanil and /or to iodinated contrast material * Intolerance to sufentanil and/or morphine * Chronic consumption of opiates * Preoperative chronic pain syndrome * Patient having a contraindication to placement of paravertebrtal catheter

Design outcomes

Primary

Measure	Time frame
morphine consumption during the first 48 hours	48 hours

Secondary

Measure	Time frame	Description
Acute pain	48 hours	using the Visual Analogue Scale (VAS) score
Biological measurements	48 hours	Oxygen saturation, level of sedation, respiratory rate, nausea, vomiting, itching, urine retention, blood pressure, heart rate
Patient satisfaction	48 hours	—
Chronic pain	3 and 6 monthes	assessed with the Saint-Antoine Pain Questionnaire (French version of the Mac Gill Pain Questionnaire) and the DN4 questionnaire.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026